

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS	RETINOID (TOPICAL)
BRAND NAME (generic)	TAZORAC (ALL TOPICAL) (tazarotene)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Tazorac (tazarotene) Cream

Tazorac Cream 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis.

Tazorac Cream 0.1% is also indicated for the topical treatment of patients with acne vulgaris.

Tazorac (tazarotene) Gel

Tazorac Gel 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement.

Tazorac Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.

The efficacy of Tazorac Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established.

Limitations of Use

The safety of Tazorac Gel use on more than 20% body surface area has not been established in psoriasis or acne.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of acne vulgaris

OR

- The requested drug is being prescribed for plaque psoriasis to treat less than or equal to 20 percent of the patient's body surface area

REFERENCES

1. Tazorac Cream [package insert]. Irvine, CA: Allergan, Inc; July 2017.
2. Tazorac Gel [package insert]. Irvine, CA: Allergan, Inc; April 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, Ohio: UpToDate, Inc.; 2021; Accessed March 8, 2021.
4. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed March 8, 2021.
5. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2016; 74:945-73.

6. Elmetts C, Korman N, Prater E, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapies and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol* 2021; 84:432-70.